186 related articles for article (PubMed ID: 25983000)
1. Differential expression and alternative splicing of cell cycle genes in imatinib-treated K562 cells.
Liu J; Lin J; Huang LF; Huang B; Xu YM; Li J; Wang Y; Zhang J; Yang WM; Min QH; Wang XZ
Tumour Biol; 2015 Sep; 36(10):8127-36. PubMed ID: 25983000
[TBL] [Abstract][Full Text] [Related]
2. A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib.
Yandim MK; Ceylan C; Elmas E; Baran Y
Tumour Biol; 2016 Feb; 37(2):2365-78. PubMed ID: 26373734
[TBL] [Abstract][Full Text] [Related]
3. miR-101 sensitizes K562 cell line to imatinib through Jak2 downregulation and inhibition of NF-κB target genes.
Farhadi E; Zaker F; Safa M; Rezvani MR
Tumour Biol; 2016 Oct; 37(10):14117-14128. PubMed ID: 27517565
[TBL] [Abstract][Full Text] [Related]
4. Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells.
Kim DS; Na YJ; Kang MH; Yoon SY; Choi CW
Korean J Intern Med; 2016 Mar; 31(2):357-66. PubMed ID: 26874514
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-1301-Mediated RanGAP1 Downregulation Induces BCR-ABL Nuclear Entrapment to Enhance Imatinib Efficacy in Chronic Myeloid Leukemia Cells.
Lin TY; Chen KC; Liu HJ; Liu AJ; Wang KL; Shih CM
PLoS One; 2016; 11(5):e0156260. PubMed ID: 27228340
[TBL] [Abstract][Full Text] [Related]
6. The antiproliferation effect of berbamine on k562 resistant cells by inhibiting NF-kappaB pathway.
Wei YL; Liang Y; Xu L; Zhao XY
Anat Rec (Hoboken); 2009 Jul; 292(7):945-50. PubMed ID: 19548306
[TBL] [Abstract][Full Text] [Related]
7. Biochemical and chemical characterization of Cynara cardunculus L. extract and its potential use as co-adjuvant therapy of chronic myeloid leukemia.
Russo A; Perri M; Cione E; Di Gioia ML; Nardi M; Cristina Caroleo M
J Ethnopharmacol; 2017 Apr; 202():184-191. PubMed ID: 28323047
[TBL] [Abstract][Full Text] [Related]
8. [Effect of cryptotanshinone on imatinib sensitivity and P-glycoprotein expression of chronic myeloid leukemia cells].
Ge YQ; Cheng RB; Yang B; Huang Z; Chen Z
Zhongguo Zhong Yao Za Zhi; 2015 Jun; 40(12):2389-95. PubMed ID: 26591531
[TBL] [Abstract][Full Text] [Related]
9. Alternative splicing of apoptosis-related genes in imatinib-treated K562 cells identified by exon array analysis.
Liu J; Xiao Y; Xiong HM; Li J; Huang B; Zhang HB; Feng DQ; Chen XM; Wang XZ
Int J Mol Med; 2012 Apr; 29(4):690-8. PubMed ID: 22211240
[TBL] [Abstract][Full Text] [Related]
10. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.
Gleixner KV; Ferenc V; Peter B; Gruze A; Meyer RA; Hadzijusufovic E; Cerny-Reiterer S; Mayerhofer M; Pickl WF; Sillaber C; Valent P
Cancer Res; 2010 Feb; 70(4):1513-23. PubMed ID: 20145140
[TBL] [Abstract][Full Text] [Related]
11. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
[TBL] [Abstract][Full Text] [Related]
12. Divalproex sodium enhances the anti-leukemic effects of imatinib in chronic myeloid leukemia cells partly through SIRT1.
Wang W; Zhang J; Li Y; Yang X; He Y; Li T; Ren F; Zhang J; Lin R
Cancer Lett; 2015 Jan; 356(2 Pt B):791-9. PubMed ID: 25449787
[TBL] [Abstract][Full Text] [Related]
13. Proteomics analysis reveals the correlation of programmed ROS-autophagy loop and dysregulated G1/S checkpoint with imatinib resistance in chronic myeloid leukemia cells.
Xu X; Yin S; Ren Y; Hu C; Zhang A; Lin Y
Proteomics; 2022 Jan; 22(1-2):e2100094. PubMed ID: 34564948
[TBL] [Abstract][Full Text] [Related]
14. In Vitro Antileukemia Activity of ZSTK474 on K562 and Multidrug Resistant K562/A02 Cells.
Zhou Q; Chen Y; Chen X; Zhao W; Zhong Y; Wang R; Jin M; Qiu Y; Kong D
Int J Biol Sci; 2016; 12(6):631-8. PubMed ID: 27194941
[TBL] [Abstract][Full Text] [Related]
15. LncRNA MALAT1 promotes cell proliferation and imatinib resistance by sponging miR-328 in chronic myelogenous leukemia.
Wen F; Cao YX; Luo ZY; Liao P; Lu ZW
Biochem Biophys Res Commun; 2018 Dec; 507(1-4):1-8. PubMed ID: 30366670
[TBL] [Abstract][Full Text] [Related]
16. ZFX Facilitates Cell Proliferation and Imatinib Resistance in Chronic Myeloid Leukemia Cells.
Wu J; Wei B; Wang Q; Ding Y; Deng Z; Lu X; Li Y
Cell Biochem Biophys; 2016 Jun; 74(2):277-83. PubMed ID: 26912059
[TBL] [Abstract][Full Text] [Related]
17. Knock-down of CIAPIN1 sensitizes K562 chronic myeloid leukemia cells to Imatinib by regulation of cell cycle and apoptosis-associated members via NF-κB and ERK5 signaling pathway.
Wang J; Li Q; Wang C; Xiong Q; Lin Y; Sun Q; Jin H; Yang F; Ren X; Pang T
Biochem Pharmacol; 2016 Jan; 99():132-45. PubMed ID: 26679828
[TBL] [Abstract][Full Text] [Related]
18. Idelalisib induces G1 arrest and apoptosis in chronic myeloid leukemia K562 cells.
Chen Y; Zhou Q; Zhang L; Wang R; Jin M; Qiu Y; Kong D
Oncol Rep; 2016 Dec; 36(6):3643-3650. PubMed ID: 27748929
[TBL] [Abstract][Full Text] [Related]
19. MiRNA-409-5p dysregulation promotes imatinib resistance and disease progression in children with chronic myeloid leukemia.
Liu YY; Jiao WY; Li T; Bao YY
Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8468-8475. PubMed ID: 31646577
[TBL] [Abstract][Full Text] [Related]
20. Correction of Bcl-x splicing improves responses to imatinib in chronic myeloid leukaemia cells and mouse models.
Zhang J; Wang Y; Li SQ; Fang L; Wang XZ; Li J; Zhang HB; Huang B; Xu YM; Yang WM; Lin J; Min QH; Liao ZH; Wu Y; Liu J
Br J Haematol; 2020 Jun; 189(6):1141-1150. PubMed ID: 32189339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
